Drug commonly used for alcoholism curbs urges of pathological gamblers

Jun 13, 2008

A drug commonly used to treat alcohol addiction has a similar effect on pathological gamblers – it curbs the urge to gamble and participate in gambling-related behavior, according to a new research at the University of Minnesota.

Seventy-seven people participated in the double-blind, placebo controlled study. Fifty-eight men and women took 50, 100, or 150 milligrams of naltrexone every day for 18 weeks. Forty percent of the 49 participants who took the drug and completed the study, quit gambling for at least one month. Their urge to gamble also significantly dropped in intensity and frequency. The other 19 participants took a placebo. But, only 10.5 percent of those who took the placebo were able to abstain from gambling. Study participants were aged 18 to 75 and reported gambling for 6 to 32 hours each week.

Dosage did not have an impact on the results, naltrexone was generally well tolerated, and men and women reported similar results.

"This is good news for people who have a gambling problem," said Jon Grant, M.D., J.D., M.P.H., a University of Minnesota associate professor of psychiatry and principal investigator of the study. "This is the first time people have a proven medication that can help them get their behavior under control."

The research is published in the June issue of the Journal of Clinical Psychiatry.

Compulsive gamblers are unable to control their behavior, and the habit often becomes a detriment in their lives, Grant said. He estimates between 1 to 3 percent of the population has a gambling problem.

While the drug is not a cure for gambling, Grant said it offers hope to many who are suffering from addiction. He also said the drug would most likely work best in combination with individual therapy.

"Medication can be helpful, but people with gambling addiction often have multiple other issues that should be addressed through therapy," he said.

Naltrexone is sold under the brand names Revia and Depade. An extended-release formulation is sold under the name Vivitrol.

Source: University of Minnesota

Explore further: Protalix signs supply deal with Brazilian govt

add to favorites email to friend print save as pdf

Related Stories

A robot that runs like a cat (w/ Video)

21 hours ago

Thanks to its legs, whose design faithfully reproduces feline morphology, EPFL's 4-legged 'cheetah-cub robot' has the same advantages as its model: It is small, light and fast.

Millions of moths mass on Madrid

4 hours ago

Millions of moths have engulfed Madrid in a population explosion blamed on spring rains, a sudden blast of summer heat and winds that have wafted them in as unwelcome guests to the Spanish capital.

Second Atlantic season tropical depression forms

4 hours ago

Tropical Depression 2 formed in the western Caribbean Sea during the early afternoon hours (Eastern Daylight Time) on June 17. NOAA's GOES-13 satellite captured an image of the storm as it consolidated enough ...

Recommended for you

Protalix signs supply deal with Brazilian govt

18 hours ago

Shares of Protalix BioTherapeutics Inc. jumped in premarket trading Wednesday after the drug developer announced a deal that requires the Brazilian government to buy at least $280 million of the company's Gaucher disease ...

EU fines pharma firms over generics delay (Update)

18 hours ago

(AP)—The European Union has fined Danish pharmaceuticals multinational Lundbeck and several other producers a combined 146 million euros ($195 million) for delaying the market entry of cheaper generic alternatives ...

Investigational drug improves sleep disorder among the blind

Jun 17, 2013

An investigational new drug significantly improved a common and debilitating circadian rhythm sleep disorder that frequently affects people who are completely blind, a multicenter study finds. The results were presented Monday ...

User comments : 0

More news stories

LA to give every student an iPad; $30M order

Los Angeles' school system, the second largest in the United States, is ordering iPads for all its students, handing Apple a major success in its quest to make the tablet computer a replacement for textbooks.